ContributorsPublishersAdvertisers

Long-Term Data Confirm Benefit of Erdafitinib in FGFR-Mutated Urothelial Carcinoma

onclive.com
 2022-01-25

The FGFR TKI erdafitinib continued to provide consistent clinical benefits with a manageable safety profile when used in the second-line treatment of patients with locally advanced or metastatic urothelial carcinoma harboring FGFR alterations. The FGFR TKI erdafitinib (Balversa) continued to provide consistent clinical benefits with a manageable safety profile...

www.onclive.com

Comments / 0

Comments / 0